Management of Post Liver Transplantation Recurrent Hepatitis C Infection with Directly Acting Antiviral Drugs: a Review

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2016 Jun 25

PMID 27337961

Citations 6

Authors

Dinesh Jothimani

Sanjay Govil

Mohamed Rela

Affiliations

Soon will be listed here.

Abstract

Recurrent HCV infection (rHCV) of the liver allograft following transplantation is universal and is associated with poor graft and patient survival in comparison with other indications. Treatment of rHCV infection in the previous era with pegylated interferon and ribavirin was associated with low sustained virological response (SVR) due to poor tolerability, adverse events and graft rejection. Recently, directly acting antiviral drugs (DAA) have been approved for the treatment of hepatitis C infection and a number of clinical trials have been conducted across various centers in the management of rHCV infection of the graft. In this review we discuss about recent studies that have emerged on the use of NS5b polymerase inhibitor, sofosbuvir in combination with second generation protease inhibitor, simeprevir, fixed dose ledipasvir or daclatasvir with or without ribavirin in the treatment of post transplant rHCV infection.

Citing Articles

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control.

Joharji H, Alkortas D, Ajlan A, Ahmed M, Al-Ashgar H, Al-Quaiz M Health Sci Rep. 2022; 6(1):e980.

PMID: 36514327 PMC: 9731361. DOI: 10.1002/hsr2.980.

Post liver transplant recurrent and de novo viral infections.

Jothimani D, Venugopal R, Vij M, Rela M Best Pract Res Clin Gastroenterol. 2020; 46-47:101689.

PMID: 33158469 PMC: 7519014. DOI: 10.1016/j.bpg.2020.101689.

Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model.

Dent M, Hamorsky K, Vausselin T, Dubuisson J, Miyata Y, Morikawa Y Cell Mol Gastroenterol Hepatol. 2020; 11(1):185-198.

PMID: 32861832 PMC: 7451001. DOI: 10.1016/j.jcmgh.2020.08.009.

Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?.

Jain A, Miller D, Schreibman I, Riley 3rd T, Krok K, Dohi T Hepatol Int. 2019; 13(2):190-198.

PMID: 30680672 DOI: 10.1007/s12072-019-09930-x.

Sofosbuvir and Ribavirin for 24 Weeks Is An Effective Treatment Option for Recurrent Hepatitis C Infection After Living Donor Liver Transplantation.

Anand A, Agarwal S, Garg H, Khanna S, Gupta S J Clin Exp Hepatol. 2017; 7(3):165-171.

PMID: 28970701 PMC: 5620355. DOI: 10.1016/j.jceh.2017.06.007.

References

Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato M . A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol. 2007; 46(6):1009-17. DOI: 10.1016/j.jhep.2006.12.017. View

Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M . HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32(4):673-84. DOI: 10.1016/s0168-8278(00)80231-7. View

Shinoda M, Ebinuma H, Itano O, Yamagishi Y, Obara H, Kitago M . Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res. 2016; 46(11):1118-1128. DOI: 10.1111/hepr.12666. View

Manns M, Samuel D, Gane E, Mutimer D, McCaughan G, Buti M . Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016; 16(6):685-697. DOI: 10.1016/S1473-3099(16)00052-9. View

Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, Mata M . Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003; 39(3):389-96. DOI: 10.1016/s0168-8278(03)00310-6. View

Rosen H, Shackleton C, Higa L, Gralnek I, FARMER D, McDiarmid S . Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol. 1997; 92(9):1453-7. View

Demetris A . Evolution of hepatitis C virus in liver allografts. Liver Transpl. 2009; 15 Suppl 2:S35-41. DOI: 10.1002/lt.21890. View

Massoumi H, Elsiesy H, Khaitova V, Peterson B, Norkus E, Grewal P . An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant. Transplantation. 2009; 88(5):729-35. DOI: 10.1097/TP.0b013e3181b2e0d1. View

Samuel D, Feray C . Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat. 2000; 7(2):87-92. DOI: 10.1046/j.1365-2893.2000.00202.x. View

10.

Herzer K, Papadopoulos-Kohn A, Achterfeld A, Canbay A, Piras-Straub K, Paul A . Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. World J Hepatol. 2015; 7(9):1287-96. PMC: 4438504. DOI: 10.4254/wjh.v7.i9.1287. View

11.

Ferrell L, Wright T, Roberts J, Ascher N, Lake J . Hepatitis C viral infection in liver transplant recipients. Hepatology. 1992; 16(4):865-76. DOI: 10.1002/hep.1840160403. View

12.

Berenguer M, Aguilera V, Rubin A, Ortiz C, Jimenez M, Prieto M . Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol. 2012; 56(6):1310-6. DOI: 10.1016/j.jhep.2011.12.031. View

13.

Jain A, Singhal A, Kashyap R, Safadjou S, Ryan C, Orloff M . Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up. Transplantation. 2011; 92(4):453-60. DOI: 10.1097/TP.0b013e3182259282. View

14.

Werner C, Egetemeyr D, Lauer U, Nadalin S, Konigsrainer A, Malek N . Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 2012; 18(12):1464-70. DOI: 10.1002/lt.23542. View

15.

Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz R . An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig. 2015; 35(5):281-9. PMC: 4544506. DOI: 10.1007/s40261-015-0279-5. View

16.

Kuo A, Terrault N . Management of hepatitis C in liver transplant recipients. Am J Transplant. 2006; 6(3):449-58. DOI: 10.1111/j.1600-6143.2005.01202.x. View

17.

Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J . Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998; 28(3):823-30. DOI: 10.1002/hep.510280333. View

18.

Ghanekar A, Kashfi A, Cattral M, Selzner N, McGilvray I, Selzner M . Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C. Transplant Proc. 2012; 44(5):1351-6. DOI: 10.1016/j.transproceed.2012.01.117. View

19.

Poordad F, Schiff E, Vierling J, Landis C, Fontana R, Yang R . Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63(5):1493-505. PMC: 5069651. DOI: 10.1002/hep.28446. View

20.

Garg V, van Heeswijk R, Lee J, Alves K, Nadkarni P, Luo X . Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011; 54(1):20-7. DOI: 10.1002/hep.24443. View